Back to search results

F-Tryptophan PET/CT for Various Cancers

This study is testing a new imaging method called F-Tryptophan PET/CT to better see and understand different cancers, including brain tumors, breast cancer, and rectal cancer. Doctors want to see if tumor tissue takes up more of a special tracer called 1-(2-[18F]FLUOROETHYL)-L-Tryptophan compared to healthy tissue. This could help them tell the difference between tumors and normal tissue more clearly. You might be able to join if you are 18 or older, have a tumor at least 1 cm in size that can be seen on imaging, and can lie still for about 70 minutes during a PET/CT scan. The study aims to see how well this tracer highlights tumors and how it moves through the body. The current status of the study is unclear.

Study design
This is an interventional study, meaning participants will receive a specific intervention. It plans to enroll 24 participants.
What's involved
You would receive a one-time injection of the radioactive tracer 1-(2-[18F]FLUOROETHYL)-L-Tryptophan and then undergo a PET/CT scan for at least 70 minutes.
Compensation
Not stated in the trial record.
Follow-up
The primary measurements are taken during the procedure, from right after tracer injection to 1-hour post-injection.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05556473

F-Tryptophan PET/CT in Human Cancers

Recruiting
PHASE1Ages 18+InterventionalDiagnostic
Barbara Ann Karmanos Cancer Institute
~24 participants
Updated 2026-01-23 on ClinicalTrials.gov
What's tested:1-(2-[18F]FLUOROETHYL)-L-Tryptophan

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The percent difference in tracer uptake values between the tumor mass and the background (non-tumor tissue)
Measured over During procedure (from right after tracer injection to 1-hour post-injection)
+1 more outcome measured

Conditions

Intracranial Glioma
Metastatic Brain Tumor
Breast Cancer
Neuroendocrine Tumors
Rectal Cancer

Explore related trials

Breast CarcinomaGliomaMalignant Brain NeoplasmNeuroendocrine NeoplasmRectal Carcinoma

Where it's being run

1 sites across 1 states
Michigan1

Study leadership

  • Csaba Juhasz, M.D.,Ph.D · PRINCIPAL_INVESTIGATOR · Barbara Ann Karmanos Cancer Institute

Who to contact

Csaba Juhasz, M.D., Ph.D
[email protected]
313-966-5136
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years.
Targeted lesion (tumor) is at least 1 cm in diameter as shown by clinical imaging.
Patient is able to lie in the PET/CT scanner for at least 70 minutes while undergoing scanning.
Women of childbearing potential must not be pregnant or breastfeeding.
Recent anatomic imaging with visible disease (tumor) for comparison with the PET/CT. .
Physical exam within 28 days of PET imaging, CBC and Multiphasic (including electrolytes, BUN, creatinine, total bilirubin, AST and ALT) within 14 days.
Patients must sign an informed consent indicating that they are aware of the investigational nature of this study.
Histopathologically confirmed, well-differentiated metastatic neuroendocrine tumor.
ECOG performance status of 2 or better.
Patients receiving stable-dose somatostatin analogs (SSAs, long-acting release \[LAR\], depot) for \>3 months before enrollment may be enrolled on the study, but such treatment is not required.
Clinical and radiological diagnosis of a breast cancer
ECOG performance status of 2 or better.
Histologically confirmed colorectal cancer, which is located in the rectum.
ECOG performance status of 2 or better.

Exclusion

Patients who are pregnant or lactating are excluded.
Severe increased intracranial pressure, status epilepticus, or other symptoms requiring emergency or urgent intervention.
Tumor surgery or radiation within 1 month prior to the PET scan
Tumor-directed therapy within 3 months to the area of planned imaging.
Ongoing treatment with a targeted agent (e.g., sunitinib or everolimus) or receiving cytotoxic chemotherapy (e.g., capecitabine or temozolomide).
Use of telotristat ethyl (a tryptophan-hydroxylase inhibitor) within one month.
Recent (within 1 month) tumor resection or radio-chemotherapy (acute/subacute post-treatment inflammatory changes may cause false positive increases on PET).
Active inflammatory bowel disease (Crohn's or Ulcerative colitis) involving the rectum.

What this trial measures

  • The percent difference in tracer uptake values between the tumor mass and the background (non-tumor tissue)During procedure (from right after tracer injection to 1-hour post-injection)

    The percent difference in 1-(2-\[18F\]fluoroethyl)-L-tryptophan tracer standardized uptake values, measured between tumor and non-tumor (normal) tissues by PET/CT imaging, in each subject, will be calculated. Mean and standard deviation of the percent differences will be calculated for each tumor type.

  • Correlation between the 1-(2-[18F]fluoroethyl)-L-tryptophan tracer uptake values and the tracer transport rates measured in the same breast tumor tissue.During procedure (from right after tracer injection to 1-hour post-injection)

    The 1-(2-\[18F\]fluoroethyl)-L-tryptophan tracer standardized uptake values and the volume of distribution (characterizing the tracer transport rates) will be measured by PET/CT imaging in the same breast tumor tissues, and the correlation of these two measures will be calculated.